@article{51cd493f4d2c429fa829dd3a60b2b826,
title = "Successful co-administration of a human rotavirus and oral poliovirus vaccines in Bangladeshi infants in a 2-dose schedule at 12 and 16 weeks of age",
abstract = "Co-administration of oral live-attenuated human rotavirus vaccine RIX4414 (Rotarix{\texttrademark}) and oral polio vaccine (OPV) was assessed. Healthy infants were randomised to receive 2-doses of either: RIX4414 or placebo co-administered with OPV (12 and 16 weeks of age); or RIX4414 or placebo given 15 days after OPV. After vaccination, 56.5-66.7% of RIX4414 and 18.6% of placebo recipients had seroconverted for rotavirus IgA. No significant differences between RIX4414 groups with or without OPV co-administration were observed. No statistically significant differences were observed between groups for polio seroprotection rates. RIX4414 vaccine was immunogenic when co-administered with OPV and did not interfere with OPV seroprotection rates.",
keywords = "Gastrointestinal disease, Oral poliovirus, Rotavirus, Vaccine",
author = "K. Zaman and Sack, {D. A.} and M. Yunus and Arifeen, {S. E.} and G. Podder and T. Azim and S. Luby and Breiman, {R. F.} and K. Neuzil and Datta, {S. K.} and A. Delem and Suryakiran, {P. V.} and Bock, {H. L.}",
note = "Funding Information: Role of funding source : This study (e-TRACK103992/ NCT00139334 ) was sponsored by GlaxoSmithKline (GSK) Biologicals, Rixensart, Belgium and the Rotavirus Vaccine Program (RVP) at the Program for Appropriate Technology in Health (PATH) in Seattle, WA, USA. RVP works in partnership with the Center for Disease Control, and Prevention (CDC) and the World Health Organisation (WHO), and is funded by the Global Alliance for Vaccines and Immunisation (GAVI). GSK Biologicals and PATH provided funding for this study. The other organisations provided advice during the study. Funding Information: This research protocol was funded by the PATH (Program for Appropriate Technology in Health) Grant #GAV-1142-07245-CRS. ICDDR, B acknowledges with gratitude the commitment of PATH to the Centre's research efforts. We thank the infants and their families for participating in this trial and other staff members for contributing in many ways to this study. ",
year = "2009",
month = feb,
day = "25",
doi = "10.1016/j.vaccine.2008.12.059",
language = "English (US)",
volume = "27",
pages = "1333--1339",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "9",
}